Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Hold” from Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have received a consensus recommendation of “Hold” from the ten brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

REPL has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. Piper Sandler lifted their target price on Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Finally, Wedbush increased their price target on Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th.

Replimune Group Price Performance

Shares of REPL stock opened at $7.54 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The company has a market capitalization of $622.60 million, a P/E ratio of -2.19 and a beta of 0.72. The company’s 50-day simple moving average is $7.54 and its two-hundred day simple moving average is $7.74. Replimune Group has a one year low of $2.68 and a one year high of $13.24.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.08. As a group, equities analysts anticipate that Replimune Group will post -2.97 EPS for the current year.

Institutional Trading of Replimune Group

A number of hedge funds have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Replimune Group by 17.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after purchasing an additional 6,653 shares during the period. Millennium Management LLC raised its holdings in shares of Replimune Group by 2.8% in the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after purchasing an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Replimune Group by 20.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock worth $6,729,000 after purchasing an additional 119,145 shares during the period. Rhumbline Advisers boosted its stake in shares of Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after purchasing an additional 6,616 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Replimune Group during the second quarter valued at approximately $583,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.